Table 1.
Clinical characteristics of samples.
Fig 1.
Analysis of scRNA-seq and bulk RNA sequencing data.
(A) UMAP plots for TN and CCRT groups; (B) UMAP embedding of single-nucleus profiles from TN and CCRT samples, with cell types color-coded; (C) Bubble charts illustrating major cell type marker genes for each cell cluster; (D) Heatmap depicting differentially expressed genes (DEGs) between TN (red) and CCRT (blue) in CC, with purple indicating low expression and yellow indicating high expression; (E) Volcano plot of DEGs, with red representing upregulated genes and blue downregulated genes; (F) Pathway enrichment analysis of 275 upregulated genes; (G) Venn diagram illustrating the overlap of upregulated genes from GSE236738 and GSE56363, identifying 33 co-upregulated genes.
Fig 2.
Construction of a radiation-resistance gene panel in CC patients to predict prognosis.
(A) Forest plot of six candidate genes predictive of radiotherapy outcomes; (B) LASSO coefficient curves for the six gene markers; (C) Partial likelihood deviance distribution for LASSO coefficients; (D) Construction of a risk score based on the Cox model; (E) Risk score distribution and PFS of enrolled patients.
Fig 3.
Cervical cancer survival analysis and target genes expression.
(A) A heatmap depicting the expression levels of four genes across 144 patients categorized into two risk groups based on the median score. The color gradient ranges from red (high expression) to blue (low expression); (B) The expression levels of GALNT3, LSM1, MPP5, and SNX7 were significantly elevated in the high-risk group compared to the low-risk group of CC patients; (C) Survival curves for both groups, based on PFS and follow-up duration; (D) A ROC curve demonstrating the prognostic accuracy of the model over one, two, three, and five years; (E) Calibration curves of a nomogram predicting overall survival (OS) at 1, 2, 3, and 5 years, based on data from the TCGA dataset.
Fig 4.
Expression of IC-related genes and infiltration of immune cells in high-risk and low-risk groups.
(A) The relative proportions of 22 immune cell types in the TCGA-CC dataset; (B) A correlation matrix for all 22 immune cell subtypes, with correlation strengths indicated by red (high), blue (low), and white (no correlation); (C) Boxplots illustrating the differences in immune cell distributions between the high-risk and low-risk groups; (D) A bubble plot highlighting the relationships between the four genes (GALNT3, LSM1, MPP5, and SNX7) and tumor-infiltrating immune cells; (E) Correlations between checkpoint gene expression in the high-risk and low-risk groups; (F) A boxplot comparing the expression levels of checkpoint genes between the high-risk and low-risk groups.
Fig 5.
IC50 of chemotherapeutic agents and Spearman correlation analysis in high-risk and low-risk groups.
(A-F) Scatter plots depicting the negative correlation between risk scores and drug IC50 (Gemcitabine, Talazoparib, Pevonedistat, AGI, Savolitinib, and Sepantronium bromide); (G-L) Box plots showing significantly higher sensitivity in the LSG group.
Fig 6.
IHC results for tumor tissues of patients resistant and sensitive to radiotherapy.
(A) IHC staining detected expression levels of four key genes (MPP5, SNX7, LSM12, and GALNT3) in CC tissues; (B) Quantification of four key radiation resistance genes in randomly selected fields of view.